Kymab Announces Kymouse Antibody Discovery Agreement With Novo Nordisk
CAMBRIDGE, England, April 22, 2013 /PRNewswire/ --
Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse™ human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases.
The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.
Dr. Tom Shepherd, Chief Business Officer of Kymab, said: "Novo Nordisk's expertise and track record in developing biological therapeutics coupled with its existing therapeutic antibody discovery infrastructure makes it an ideal partner for Kymab. Our strategy is to partner the Kymouse platform broadly to maximise its potential in the discovery and development of new medicines."Hanne Risager Romedahl, Vice President, Head of ImmunoTechnology, Novo Nordisk, said "Antibody therapeutics have great potential to advance patient care in diseases with significant unmet medical need. Kymab's highly innovative and technically advanced Kymouse platform is an excellent fit with our existing therapeutic antibody discovery capability." The financial terms of the agreement were not disclosed, but include platform licence fees, development milestone payments for drug candidates and royalties on sales of antibodies discovered using the Kymouse strains. About Kymab Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform. Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV